US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% AAPL $333.69 ▲+1.02%
FinancialContent

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.690 +0.010 (+0.27%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024. 
Via Talk Markets
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Dow Surges Over 100 Points; ModivCare Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial ↗
Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program. 
Via Benzinga
News headline image
US Stocks Mixed; Producer Prices Increase In August ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in... 
Via Benzinga
News headline image
Fulcrum Therapeutics to Participate in Upcoming September Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
8 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 ↗
FULC stock results show that Fulcrum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Participate in Upcoming May Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >